Patents Assigned to Institute Pasteur
  • Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
    Patent number: 11305003
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue vims (DENV) infections in a human subject.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 19, 2022
    Assignees: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude Roth, Etienne Simon-Loriere, Anavaj Sakuntabhai, Felix Delgado
  • METHOD FOR ACTIVATING CD4+T CELL
    Publication number: 20220111040
    Abstract: Provided is a method for activating CD4+ T cells using a polymer-based antigen complex. The method comprises the steps of bringing the polymer-based antigen complex into contact with B cells so that B cells process and present the antigen complex, and of bringing the B cells into contact with CD4+ T cells to activate CD4+ T cells. Also provided are a method for promoting the differentiation of CD4+ T cells into Tfh cells and Thl cells using the antigen complex, and a method for treating diseases by activating CD4+ T cells and/or promoting the differentiation of CD4+ T cells.
    Type: Application
    Filed: August 6, 2019
    Publication date: April 14, 2022
    Applicants: INSTITUTE OF BIOPHYSCIS, CHINESE ACADEMY OF SCIENCES, INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES
    Inventors: Baidong HOU, Sheng HONG, Zhaolin HUA, Hong TANG
  • Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptoms and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s)
    Patent number: 11287433
    Abstract: The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: March 29, 2022
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT A L'ENERGIE ATOMIOUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti, Alain Sarasin, Denis Biard
  • Anti-infective compounds
    Patent number: 11279714
    Abstract: The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: March 22, 2022
    Assignee: INSTITUT PASTEUR KOREA
    Inventors: Jaeseung Kim, Sunhee Kang, Juhee Kang, Sumi Lee, Jeong Jea Seo, Mooyoung Seo
  • Immunoresponsive methods of treating tumors
    Patent number: 11246858
    Abstract: Within the scope of the present invention is a new pharmacological strategy for the treatment of tumors based on anti-tumoral immune responses.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: February 15, 2022
    Assignee: INSTITUT PASTEUR DE MONTEVIDEO
    Inventors: Marcelo Hill, Mercedes Segovia, Sofia Russo, Mathias Jeldres, Maria Romina Girotti, Maite Duhalde Vega, Yamil Damián Mahmoud
  • Immunological signatures and parameters predicting therapeutic responses to anti-TNF therapy
    Patent number: 11249090
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 15, 2022
    Assignees: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: Lars Rogge, Silvia Menegatti, Maxime Dougados, Elisabetta Bianchi
  • SEVERE ACUTE RESPIRATORY SYNDROME (SARS) - ASSOCIATED CORONAVIRUS DIAGNOSTICS
    Publication number: 20220042987
    Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.
    Type: Application
    Filed: February 3, 2021
    Publication date: February 10, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Sylvie VAN DER WERF, Nicolas ESCRIOU, Caroline DEMERET, Stéphane PETRES, Pierre LAFAYE, Jacques BELLALOU
  • Means for diagnosing, predicting or monitoring pneumonia
    Patent number: 11236390
    Abstract: The application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP). The means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient. The means of involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes. The first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein or the P. jirovecii mitochondrial Small Sub-Unit (mtSSU) gene. The second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, e.g., be the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 1, 2022
    Assignees: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Alexandre Alanio, Stéphane Bretagne, Françoise Dromer, Aude Sturny-Leclere, Benjamin Hommel, Marion Benazra
  • STAPLED PEPTIDE INHIBITORS OF NEMO AS POTENTIAL ANTI-INFLAMMATORY AND ANTI-CANCER DRUGS
    Publication number: 20220025002
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 27, 2022
    Applicant: INSTITUT PASTEUR
    Inventors: Fabrice AGOU, Alix BOUCHARLAT, Yves-Marie COIC, Françoise BALEUX
  • Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
    Patent number: 11229645
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 25, 2022
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
    Patent number: 11226343
    Abstract: The present invention relates to methods and kits for diagnosing a postoperative pulmonary infection in a patient who underwent surgery. More particularly, the present invention relates to a method for diagnosing a postoperative pulmonary infection in a patient who underwent surgery, comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said patient, at a time point comprised between 3 h and 30 h after surgery.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: January 18, 2022
    Assignees: BIOTHELIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LE RECHERCHE MEDICAL), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, UNIVERSITE DE LILLE
    Inventors: Philippe Lasalle, Sidney Chocron, Nathalie De Freitas Caires
  • Variants of terminal deoxynucleotidyl transferase and uses thereof
    Patent number: 11208637
    Abstract: The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: December 28, 2021
    Assignees: DNA Script SAS, Institut Pasteur, National Center for Scientific Research (CNRS)
    Inventors: Elise Champion, Mikhael Soskine, Thomas Ybert, Marc Delarue
  • BACTERIOPHAGE THERAPY
    Publication number: 20210386805
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Application
    Filed: June 21, 2021
    Publication date: December 16, 2021
    Applicants: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux
  • Anti-dengue vaccines and antibodies
    Patent number: 11198706
    Abstract: A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and/or d) is presented on a dimer of Envelope proteins; and/or c) is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: December 14, 2021
    Assignees: IMPERIAL COLLEGE INNOVATIONS LIMITED, INSTITUT PASTEUR, UNIVERSITE PARIS-SACLAY
    Inventors: Screaton Gavin, Juthathip Mongkolsapaya, Alexander Rouvinski, Pablo Guardado-Calvo, Giovanna Barba-Spaeth, Stéphane Duquerroy, Marie-Christine Vaney, Felix Augusto Rey
  • OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
    Publication number: 20210380993
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: December 9, 2021
    Applicants: Eligo Bioscience, Institut Pasteur
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Lebecetin, a C-type lectin, as neovascularization inhibitor
    Patent number: 11191807
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 7, 2021
    Assignees: SARBONNE INIVERSIÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE TUNIS
    Inventors: Xavier Guillonneau, Fadoua Montassar, Naziha Marrakchi, Erij Messadi, Florian Sennlaub, José-Alain Sahel
  • Live recombinant measles-M2 virus—its use in eliciting immunity against influenza viruses
    Patent number: 11160858
    Abstract: The invention relates to an active ingredient which is a live attenuated recombinant measles virus expressing influenza A virus antigen(s) and to its use in the elicitation of immunity, in particular protective immunity and advantageously broad-spectrum protective immunity against influenza A virus. In particular, the influenza A virus is selected among epidemic seasonal viruses and/or endemic viruses circulating in the human population and advantageously encompasses a pandemic virus such as H1N1v.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 2, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Nicolas Robert Xavier Escriou, Frederic Tangy, Ho Hong Hai Vo
  • Stapled peptide inhibitors of NEMO as potential anti-inflammatory and anti-cancer drugs
    Patent number: 11149070
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: October 19, 2021
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient
    Patent number: 11149033
    Abstract: The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 19, 2021
    Assignees: INSTITUT PASTEUR KOREA, ST PHARM CO., LTD.
    Inventors: Ji Young Min, So Young Chang, Ji Hye Lee, Sun Hee Kang, Sun Ju Kong, Su Yeon Jo, Young Mi Kim, Junghwan Choi
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 11124563
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: September 21, 2021
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger